Singer Yang Hee-eun reveals April cancer surgery following ovarian battle decades prior
South Korean singer Yang Hee-eun underwent cancer surgery in April 2026, she disclosed in a YouTube video released on Sept. 18, 2026. The procedure occurred roughly 40 years after she was diagnosed with terminal ovarian cancer at age 30 and given a three-month prognosis, a condition she survived following surgery and subsequent recovery. It remains unconfirmed whether the 2026 diagnosis represents a recurrence or metastasis of her previous ovarian cancer or a newly developed primary malignancy.
The detection of a new tumor following prior cancer treatment requires distinguishing between a direct recurrence and an entirely separate diagnosis known as a secondary cancer. According to Dr. Choi Soo-jung, a family medicine professor at Gachon University Gil Medical Center, understanding these distinctions helps shape appropriate monitoring and screening protocols for cancer survivors.
Recurrence, Metastasis, and the Distinct Definition of Secondary Cancers
Cancer discovered after a successful initial treatment falls into two distinct categories: recurrence, metastasis, or a secondary cancer. Recurrence happens when surviving cancer cells multiply at or near the original tumor site. Metastasis occurs when malignant cells travel through blood or lymphatic vessels to distant organs, retaining the diagnosis name of the primary site even when discovered elsewhere.
Conversely, a secondary cancer is an independent malignancy that develops separately from the initial disease, often appearing long after the first cancer has been successfully treated. A large-scale 2020 study published in the Journal of the American Medical Association (JAMA) tracking approximately 1.54 million U.S. adults who survived at least five years past a cancer diagnosis found that men faced an 11% higher risk and women a 10% higher risk of developing a secondary cancer compared to the general population. A subsequent 2024 South Korean study analyzing adult five-year cancer survivors revealed an even sharper disparity, showing a 28% elevated risk of secondary malignancies among survivors under the age of 40.
Pediatric and adolescent populations also face documented risks. Citing a 2019 study in the Journal of Clinical Oncology (JCO), Choi noted that among North American pediatric and adolescent cancer survivors who lived past five years post-diagnosis, those treated exclusively with chemotherapy without radiation still faced a secondary cancer risk 2.8 times higher than the general population.
Four Primary Risk Factors Driving Post-Treatment Malignancies
Secondary cancers emerge from a complex interplay of treatment side effects, inherited genetics, environmental habits, and persistent infections, according to Choi.
* Lifestyle Habits: Patients often resume habits that contributed to their initial diagnosis. The JAMA study noted that many secondary tumors included smoking-related lung cancers and obesity-linked colorectal cancers. Choi emphasized that smoking cessation often lapses over time, increasing risks for lung, bladder, esophagus, and head and neck cancers. Alcohol consumption further amplifies these dangers.
* Treatment Side Effects: Radiation therapy and specific chemotherapeutic agents elevate risks. Radiation increases the probability of secondary tumors near the treatment field—such as breast, lung, or thyroid cancers following chest irradiation—with the danger rising alongside higher radiation doses and younger patient ages. Certain chemotherapy drugs elevate leukemia risks, typically peaking between two and 10 years post-treatment. Despite these risks, the Canadian Cancer Association notes that the survival benefits of necessary cancer treatments far outweigh secondary cancer risks.
* Genetic Predispositions: Inherited mutations, such as BRCA gene alterations tied to breast and ovarian cancers, heighten susceptibility to multiple malignancies. Choi recommends genetic counseling and testing for individuals diagnosed at a young age, those with multiple distinct cancers, or people with strong family cancer histories.
* Persistent Infections: Ongoing viral presence, including chronic hepatitis B or C or persistent human papillomavirus (HPV) infections, can spur new virus-linked cancers such as hepatocellular carcinoma or cervical and anal cancers after a patient beats an unrelated primary disease.
Differentiating Follow-Up Surveillance From Standard Age-Appropriate Cancer Screenings
Surveillance after cancer treatment involves two distinct types of evaluations: tracking tests designed to catch a recurrence of the initial cancer, and separate cancer screenings aimed at detecting entirely new, unrelated malignancies in other organs. While follow-up care focuses heavily on the original site, survivors require independent general screenings.
Choi stated that adult cancer survivors should continue standard population-level screening guidelines for colorectal, breast, cervical, and lung cancers unless specific treatment exposures dictate otherwise. However, targeted therapies alter these baselines. Women who received chest radiation between ages 10 and 30 are advised to undergo annual mammograms and breast MRIs starting either 8 to 10 years post-treatment or at age 25, whichever comes later. Patients with chest radiation histories and smoking backgrounds may utilize low-dose chest computed tomography (CT) scans for lung monitoring, while abdominal or pelvic radiation recipients often begin colonoscopies earlier than the general population. Individuals exposed to leukemia-linked chemotherapy undergo routine clinical checkups and blood panels.
Lifestyle Adjustments and Personal Treatment Record Management
Maintaining healthy habits remains vital for mitigating both recurrence and secondary cancer risks. Choi emphasized that quitting smoking, exercising regularly, limiting alcohol intake, and managing body weight serve as foundational protective measures. Maintaining written documentation detailing specific chemotherapy drugs, cumulative dosages, and radiation field locations helps clinicians determine precise screening schedules tailored to an individual's unique risk profile. Regular consultations with a primary physician ensure that screening intervals adapt safely to changing health needs over time.
Worth a look